OncLive | Bringing the Global Oncology Community Together

The combination of palbociclib plus fulvestrant leads to a clinically meaningful benefit in overall survival in patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer who had progressed or relapsed... Read More >>

ESMO 2018: RCC Gene Signatures Validated for Treatment Benefit

ESMO 2018: Atezolizumab Combo Improves PFS in Frontline Metastatic TNBC

ESMO 2018: Adding Radium-223 to Abiraterone Shows No Survival Advantage in mCRPC

ESMO 2018: MET, EGFR C797S Linked With Acquired Resistance to Frontline Osimertinib in NSCLC

Personalized Therapy Becoming Reality in Pancreatic Cancer

View More Stories >>

View Conference Coverage

2018 State of the Science Summit on Hematologic Malignancies in Clayton

State of the Science Summit on GI Cancers in Newport Beach

2018 ESMO Congress

2018 State of the Science Summit on Hematologic Malignancies in Cleveland

2018 Lynn Sage Breast Cancer Symposium

Dr. Cristofanilli on Survival Findings From the PALOMA-3 Trial

Dr. Rosenberg on Dosing of Nivolumab Plus Ipilimumab in Bladder Cancer

Dr. Kahl on Ibrutinib in CLL

Dr. Vij on the Optimal Induction Therapy in Multiple Myeloma

Dr. Oh on the Development of JAK Inhibitors in Myelofibrosis

OncLive houses thousands of videos that provide updates and information.
See more Videos

Take-Home Messages on the NSCLC Treatment Paradigm

Other Targeted Approaches in NSCLC: NTRK or RET Fusions

Considering Targeted Agents in BRAF-Mutant NSCLC

Sequencing Therapies in ALK-Rearranged NSCLC

Changing the Treatment Paradigm for ALK-Rearranged NSCLC

Global Perspectives on Use of Osimertinib in EGFR+ NSCLC

Osimertinib's Role in EGFR+ Metastatic Lung Cancer

OncLive houses thousands of videos that provide updates and information.
See more Videos

Future Management of Metastatic Colorectal Cancer

Emerging Therapy in Metastatic Colorectal Cancer

BEACON Trial: Triplet Therapy in BRAF V600E

Moving the AML Treatment Landscape Forward

Optimizing the Use of FLT3 Inhibitor Therapy for AML

Long-Term Challenges With FLT3 Inhibition in AML

OncLive houses thousands of videos that provide updates and information.
See more Videos

Featured

Expert Anticipates Cure in Acute Lymphoblastic Leukemia

Elias Jabbour, MD, discussed recent clinical trial results in acute lymphoblastic leukemia, the role of immunotherapy, and the biggest challenges facing the field.

View more >>>

Featured

Dr. Ramchandren on the North American Results of the ECHELON-1 Study in Hodgkin Lymphoma

Radhakrishnan Ramchandren MD, associate professor, Wayne State University School of Medicine, Barbara Ann Karmanos Cancer Institute, discusses the North American results of the ECHELON-1 study in Hodgkin lymphoma.

View more >>>